Donepezil Viatris

Donepezil Viatris is an oral tablet that contains the active ingredient donepezil hydrochloride. Marketed in the European Union as a prescription‑only medication, it belongs to the acetylcholinesterase inhibitor class and is used to manage symptoms of Alzheimer’s disease. The product is manufactured by Viatris and is classified under ATC code N06DA02. Its specific strength and dosage form are not disclosed in the currently available data.

Donepezil Viatris is indicated for the symptomatic treatment of mild to moderate Alzheimer’s disease, where it may improve cognition and daily functioning.

- Treatment of mild to moderate Alzheimer’s disease to support cognitive function. - Adjunct therapy for patients with early‑stage Alzheimer’s disease. - Use as part of a comprehensive care plan that includes non‑pharmacologic interventions. - May be considered when cholinergic deficits are identified as contributing to memory impairment. - Potential use in combination with other Alzheimer’s medications such as memantine under physician guidance. - May be prescribed for patients who have demonstrated a decline in activities of daily living attributable to Alzheimer’s disease.

Side effects reported with donepezil, the active component of Donepezil Viatris, vary in frequency and severity.

Common: - Nausea, vomiting, or upset stomach, often occurring early in treatment. - Diarrhea or loose stools, which may be mild to moderate. - Insomnia, vivid dreams, or other sleep disturbances. - Muscle cramps, weakness, or general fatigue.

Serious: - Severe bradycardia, heart block, or syncope, requiring medical evaluation. - Gastrointestinal bleeding or ulceration, especially in patients with risk factors. - Hepatotoxicity manifested as elevated liver enzymes or jaundice.

When prescribing Donepezil Viatris, clinicians should consider several precautions to ensure safe use.

- Assess cardiac history; avoid in patients with sick sinus syndrome or recent myocardial infarction. - Monitor for signs of gastrointestinal bleeding, especially in patients on NSAIDs or anticoagulants. - Evaluate liver function before initiation and periodically during therapy. - Use caution in patients with asthma or chronic obstructive pulmonary disease due to possible bronchospasm. - Adjust dose or discontinue if severe bradycardia or syncope occurs. - Counsel patients about potential sleep disturbances and advise on bedtime dosing.

Donepezil may interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid: - Concurrent use with strong anticholinergic agents (e.g., atropine, scopolamine) that counteract cholinergic activity. - Co‑administration with drugs that significantly prolong the QT interval.

Use with caution: - Beta‑blockers or calcium channel blockers, as additive bradycardic effects may occur. - NSAIDs, aspirin, or anticoagulants, which can increase risk of gastrointestinal bleeding. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) may raise donepezil plasma levels. - Memantine or other Alzheimer’s agents, requiring dose adjustments and clinical monitoring.